The Pharma Data

NOVEMBER 3, 2020

Deucravacitinib works by inhibiting the tyrosine kinase 2 (TYK2) enzyme, which is linked to an immune response that causes skin inflammation. Bristol Myers Squibb (BMS) has reported positive results from a late-stage trial of its investigational drug, BMS-986165 (deucravacitinib), for treating moderate-to-severe plaque psoriasis.

Immune Response 52

Immune Response Drugs Trials Disease 52

The Pharma Data

DECEMBER 11, 2020

The university and CSL said while a phase 1 study evaluating candidate v451 showed it delivered a strong immune response and had a positive safety profile, vaccine trials will not progress to phase 2/3 trials given the possibility of interference with HIV tests.

Vaccine 52

Vaccine Immune Response Trials Government 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S.

Vaccine 52

Vaccine Immune Response Trials Research 52

SugarCone Biotech

MARCH 24, 2025

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Today, however, we turn to the TCE therapeutic class. Both explanations are plausible, but the relevant clinical data are limited. Proc Natl Acad Sci U S A 115: E2068-E2076.

Immune Response 64

Immune Response Therapies Treatment Disease 64

The Pharma Data

DECEMBER 20, 2020

The vaccine “could have significant advantages over first-generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long- term protection,” Scancell said. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 14, 2020

The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated. “We are hopeful that this trial will continue to demonstrate the impact of mRNA technology,” said CureVac CEO Franz-Werner Haas.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

APRIL 15, 2022

Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike. The 50% neutralizing geometric mean titer (GMT) against Omicron was 993 (after three doses), compared to 27 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. BOSTON, Oct. Morgan Securities LLC, SVB Leerink LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

NOVEMBER 16, 2020

Interim data from an early-stage trial indicated JNJ-78436735 delivered an immune response and was well-tolerated. The first part of the study, also enrolling 30,000 participants, is testing whether a single-dose regimen is effective. Jason Scott.

Vaccine 40

Vaccine Trials Immune Response Research 40

The Pharma Data

NOVEMBER 18, 2020

While the vaccine generated immune responses in participants, it led to lower levels of antibodies than were seen in patients that recovered from COVID-19, the researchers said in The Lancet. James Miessler. Source link.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

DECEMBER 16, 2020

16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. GAITHERSBURG, Md., About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

09, 2020 (GLOBE NEWSWIRE) — Qu Biologics Inc. , a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing. VANCOUVER, British Columbia, Dec.

Immune Response 52

Immune Response Clinical Trials Disease Trials 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Allergic reactions to vaccines are generally rare and people with common allergies are not more likely to have a reaction to the Pfizer-BioNTech COVID-19 vaccine, according to guidance released by the American College of Allergy, Asthma & Immunology (ACAAI). . © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

JUNE 25, 2021

CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions. References Sun D, et al. 2022.02.002.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

Drug Target Review

FEBRUARY 28, 2024

Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. She previously served as the VP and AVP of Operations and Innovation since August 2020. Cells 9(40):800 (2020). Holtmeier W, Kabelitz D.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Research Doctors Treatment 52

The Pharma Data

JANUARY 22, 2021

24, 2020 ). The Weinreich article also reports that the “antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

OCTOBER 15, 2020

A new Micronutrient survey manual (2020 ) and toolkit, developed in collaboration by WHO, CDC, UNICEF and Nutrition International were published today to meet the demand of countries interested in assessing the micronutrient status of their populations. Addressing micronutrient malnutrition is one of the greatest global health challenges.

Immune Response 52

Immune Response International Government Research 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ).

Vaccine 40

Vaccine Immune Response RNA Virus 40

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

DECEMBER 23, 2020

24, 2020 07:00 UTC. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. © 2020 HealthDay. Posted: December 2020. FRIDAY, Dec. regulators. Short answer: Yes. All rights reserved.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. Dr Hussam Shaheen, Director of Antibody Discovery and Engineering at Pandion Therapeutics, said: “Our TALON platform leverages natural immune regulatory mechanisms, to re-balance immune responses and ultimately advance discovery into novel treatments for autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Vaccine 52

Vaccine Immune Response Pharma Companies Virus 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The agreement was first expanded in March 2020 to include development of a novel mRNA vaccine for COVID-19. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52